PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12204800-0 2002 The Arg allele in position 192 of PON1 is associated with carotid atherosclerosis in subjects with elevated HDLs. Arginine 4-7 paraoxonase 1 Homo sapiens 34-38 12368388-2 2002 Serum PON1 activity and PON1-mediated capacity of HDL to prevent lipoprotein oxidation are modulated by two common polymorphisms at positions 192 (Gln-->Arg) and 55 (Leu-->Met) of the PON1 gene. Arginine 156-159 paraoxonase 1 Homo sapiens 6-10 12368388-2 2002 Serum PON1 activity and PON1-mediated capacity of HDL to prevent lipoprotein oxidation are modulated by two common polymorphisms at positions 192 (Gln-->Arg) and 55 (Leu-->Met) of the PON1 gene. Arginine 156-159 paraoxonase 1 Homo sapiens 24-28 12368388-2 2002 Serum PON1 activity and PON1-mediated capacity of HDL to prevent lipoprotein oxidation are modulated by two common polymorphisms at positions 192 (Gln-->Arg) and 55 (Leu-->Met) of the PON1 gene. Arginine 156-159 paraoxonase 1 Homo sapiens 24-28 12204800-15 2002 On the other hand, in subjects with elevated concentration of HDL cholesterol, the presence of carotid atherosclerosis is significantly associated with the arginine variant in position 192 of the PON1 gene. Arginine 156-164 paraoxonase 1 Homo sapiens 196-200 12059071-5 2002 The PON1 gene has two common coding region polymorphisms, Leu55-->Met and Gln192-->Arg. Arginine 89-92 paraoxonase 1 Homo sapiens 4-8 12052975-3 2002 Two common polymorphisms in the PON1 gene, the 192 Gln (Q) --> Arg (R) and 55 Leu (L) --> Met (M) substitutions, determine interindividual variation in PON1 activity. Arginine 66-69 paraoxonase 1 Homo sapiens 32-36 12052975-3 2002 Two common polymorphisms in the PON1 gene, the 192 Gln (Q) --> Arg (R) and 55 Leu (L) --> Met (M) substitutions, determine interindividual variation in PON1 activity. Arginine 66-69 paraoxonase 1 Homo sapiens 158-162 12052142-2 2002 The PON1 activity polymorphism is determined mainly by a glutamine(Q)/arginine(R) substitution at position 192 of PON1 (PON1(Q192R)). Arginine 70-78 paraoxonase 1 Homo sapiens 4-8 12052142-2 2002 The PON1 activity polymorphism is determined mainly by a glutamine(Q)/arginine(R) substitution at position 192 of PON1 (PON1(Q192R)). Arginine 70-78 paraoxonase 1 Homo sapiens 114-118 12052142-2 2002 The PON1 activity polymorphism is determined mainly by a glutamine(Q)/arginine(R) substitution at position 192 of PON1 (PON1(Q192R)). Arginine 70-78 paraoxonase 1 Homo sapiens 114-118 12575193-0 2002 [The paraoxonase Gln-Arg 192 polymorphism in patients with endogenous hypertriglyceridemia in Chinese population]. Arginine 21-24 paraoxonase 1 Homo sapiens 5-16 11395042-0 2001 Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study. Arginine 63-66 paraoxonase 1 Homo sapiens 93-105 12575193-8 2002 CONCLUSION: These may be an association of the QQ genotype of the paraoxonase 192 Gln-Arg polymorphism with the decrease of serum apoA I level and the increase of serum apoE level in endogenous hypertriglyceridemica. Arginine 86-89 paraoxonase 1 Homo sapiens 66-77 11257265-3 2001 Two frequent mutations at the paraoxonase gene locus (PON1) underlie the leucine (Leu allele) --> methionine (Met allele) and the glutamine(Gln allele) --> arginine(Arg allele) aminoacid substitutions at residues 55 and 192, respectively. Arginine 162-170 paraoxonase 1 Homo sapiens 54-58 11257265-3 2001 Two frequent mutations at the paraoxonase gene locus (PON1) underlie the leucine (Leu allele) --> methionine (Met allele) and the glutamine(Gln allele) --> arginine(Arg allele) aminoacid substitutions at residues 55 and 192, respectively. Arginine 171-174 paraoxonase 1 Homo sapiens 54-58 10978258-2 2000 Its activity is modulated by 2 common amino acid polymorphisms at positions 192 (Gln-->Arg) and 55 (Met-->Leu) in the paraoxonase gene (P:ON1). Arginine 90-93 paraoxonase 1 Homo sapiens 124-135 11409295-6 2001 In contrast, in the subgroup of type 2 diabetic patients the PON1 192 Arg allele conferred about twice the risk of cerebrovascular stenosis compared to those homozygous for the Gln allele (Odds ratio 2.00, 95%-CI 0.92-4.38). Arginine 70-73 paraoxonase 1 Homo sapiens 61-65 11409295-8 2001 The observed interaction with type 2 diabetes, however, is supporting the hypothesis that the effect of the PON1 192 Arg allele on atherosclerosis is modulated by other risk factors like diabetes. Arginine 117-120 paraoxonase 1 Homo sapiens 108-112 10978258-2 2000 Its activity is modulated by 2 common amino acid polymorphisms at positions 192 (Gln-->Arg) and 55 (Met-->Leu) in the paraoxonase gene (P:ON1). Arginine 90-93 paraoxonase 1 Homo sapiens 142-147 10831526-1 2000 BACKGROUND: Human serum paraoxonase (PON1) exists in two polymorphic forms: one that differs in the amino acid at position 192 (glutamine and arginine, Q and R, respectively) and the second one that differs in the amino acid at position 55 (methionine and leucine, M and L, respectively). Arginine 142-150 paraoxonase 1 Homo sapiens 37-41 10894822-4 2000 We examined whether 2 common polymorphisms of the paraoxonase (PON1) gene leading to a methionine (M allele)-leucine (L allele) interchange at position 54 and an arginine (B allele)-glutamine (A allele) interchange at position 191 are associated with the presence and progression of WMLs. Arginine 162-170 paraoxonase 1 Homo sapiens 63-67 10831161-0 2000 Differential effects of smoking on myocardial infarction risk according to the Gln/Arg 192 variants of the human paraoxonase gene. Arginine 83-86 paraoxonase 1 Homo sapiens 113-124 10831161-3 2000 PON1 genetic polymorphism includes PON1 Q, an isoform with a low activity toward paraoxon hydrolysis that has a glutamine at position 192, and PON1 R, the high-activity isoform with an arginine at position 192. Arginine 185-193 paraoxonase 1 Homo sapiens 0-4 10729387-3 2000 Two frequent mutations at the paraoxonase gene locus (PON1) are the leucine (L allele)-->methionine (M allele) and the glutamine (Q allele)-->arginine (R allele) substitutions at residues 55 and 192, respectively. Arginine 148-156 paraoxonase 1 Homo sapiens 30-41 10729387-3 2000 Two frequent mutations at the paraoxonase gene locus (PON1) are the leucine (L allele)-->methionine (M allele) and the glutamine (Q allele)-->arginine (R allele) substitutions at residues 55 and 192, respectively. Arginine 148-156 paraoxonase 1 Homo sapiens 54-58 11480456-3 2000 The PON1 genetic polymorphisms of 192 Gln/Arg and 55 Leu/Met in the amino acid sequence are partly involved in the PON1 enzyme activity. Arginine 42-45 paraoxonase 1 Homo sapiens 4-8 10677395-2 2000 PON1 has two genetic polymorphisms, both due to amino acid substitutions: one involving glutamine (Q genotype) and arginine (R genotype) at position 192, and the other involving leucine (L genotype) and methionine (M genotype) at position 55. Arginine 115-123 paraoxonase 1 Homo sapiens 0-4 11480456-3 2000 The PON1 genetic polymorphisms of 192 Gln/Arg and 55 Leu/Met in the amino acid sequence are partly involved in the PON1 enzyme activity. Arginine 42-45 paraoxonase 1 Homo sapiens 115-119 10599538-2 1999 A polymorphism at codon 192 (Gln/Arg) of the PON1 gene gives rise to two isoforms that differ in substrate-dependent activity. Arginine 33-36 paraoxonase 1 Homo sapiens 45-49 10411705-2 1999 There are two common PON1 polymorphisms at position 55 (Leu-Met change) and 192 (Gln-Arg change) of the amino acid chain. Arginine 85-88 paraoxonase 1 Homo sapiens 21-25 9763534-2 1998 A common polymorphism of the paraoxonase gene (PON1) involving a Gln-to-Arg interchange at position 192 has been demonstrated to modulate PON activity toward paraoxon, a nonphysiological substrate; Arg192 (allele B) is associated with higher activity than Gln192 (allele A). Arginine 72-75 paraoxonase 1 Homo sapiens 29-40 9763534-2 1998 A common polymorphism of the paraoxonase gene (PON1) involving a Gln-to-Arg interchange at position 192 has been demonstrated to modulate PON activity toward paraoxon, a nonphysiological substrate; Arg192 (allele B) is associated with higher activity than Gln192 (allele A). Arginine 72-75 paraoxonase 1 Homo sapiens 47-51 9763534-2 1998 A common polymorphism of the paraoxonase gene (PON1) involving a Gln-to-Arg interchange at position 192 has been demonstrated to modulate PON activity toward paraoxon, a nonphysiological substrate; Arg192 (allele B) is associated with higher activity than Gln192 (allele A). Arginine 72-75 paraoxonase 1 Homo sapiens 47-50 9712341-2 1998 PON1 has two genetic polymorphisms both due to amino acid substitution, one involving glutamine (A genotype) and arginine (B genotype) at position 192 and the other leucine (L genotype) and methionine (M genotype) at position 55. Arginine 113-121 paraoxonase 1 Homo sapiens 0-4 9829330-2 1998 Paraoxonase serum activity varies among individuals due to an Gln/Arg polymorphism with low (A phenotype) and high activity (B phenotype). Arginine 66-69 paraoxonase 1 Homo sapiens 0-11 9690920-2 1998 Its activity is mainly determined by a gene polymorphism of the PON 1 gene (Glu-Arg 192). Arginine 80-83 paraoxonase 1 Homo sapiens 64-69 9746266-3 1998 PON1 exhibits two sequence polymorphisms, Arg-->Gln 192 and Met-->Leu 55, respectively, of which the former is responsible for the distinct catalytic activity of the two corresponding allozymes against paraoxon. Arginine 42-45 paraoxonase 1 Homo sapiens 0-4 1657140-7 1991 The amino acid sequence accounting for 42% of rabbit paraoxonase was determined by (1) gas-phase sequencing of the intact protein and (2) peptide fragments from lysine and arginine digests. Arginine 172-180 paraoxonase 1 Homo sapiens 53-64 8960946-3 1996 It has been hypothesized an A/B (Gln 192-->Arg) polymorphism of PON may be involved in the pathogenesis of CHD, especially among subjects with non-insulin-dependent diabetes mellitus (NIDDM). Arginine 46-49 paraoxonase 1 Homo sapiens 67-70 8902155-0 1996 The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Arginine 8-11 paraoxonase 1 Homo sapiens 34-45 8902155-0 1996 The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Arginine 8-11 paraoxonase 1 Homo sapiens 47-50 8902155-2 1996 We studied the Gln/Arg polymorphism affecting codon 192 of human paraoxonase (PON 192) to determine whether this polymorphism, which is associated with serum paraoxonase (PON) activity, represents a risk factor for myocardial infarction (MI). Arginine 19-22 paraoxonase 1 Homo sapiens 65-76 8902155-5 1996 The frequency of the PON 192/Arg allele in 405 MI patients who underwent coronary angiography was 0.295, 0.323 and 0.331, respectively in those with 1, 2 or 3 stenosed arteries (stenosis > 50%) (ns). Arginine 29-32 paraoxonase 1 Homo sapiens 21-24 8098250-3 1993 We demonstrate that arginine at position 192 specifies high activity PON whereas a glutamine specifies the low activity variant. Arginine 20-28 paraoxonase 1 Homo sapiens 69-72 25112958-4 2015 The enzymatic activity of PON1 against OPs depends on the genetic polymorphisms present at position 192 (glutamine or arginine). Arginine 118-126 paraoxonase 1 Homo sapiens 26-30 33260536-3 2020 The PON1-Q192R polymorphism involves a change from glutamine (Q variant) to arginine (R variant) at position 192 of the PON1 protein and affects its enzymatic activity. Arginine 76-84 paraoxonase 1 Homo sapiens 4-8 33260536-3 2020 The PON1-Q192R polymorphism involves a change from glutamine (Q variant) to arginine (R variant) at position 192 of the PON1 protein and affects its enzymatic activity. Arginine 76-84 paraoxonase 1 Homo sapiens 120-124 26795139-2 2016 PON1 has two genetic polymorphisms both due to amino acid substitution, one involving glutamine and arginine at position 192 and the other leucine and methionine at position 55. Arginine 100-108 paraoxonase 1 Homo sapiens 0-4 32478190-8 2020 The result revealed 94.9% polymorphism of PON1 Q192R, which was higher in the R/R (Arg/Arg) genotypes than Q/R (Gln/Arg) and lowest in Q/Q (Gln/Gln) genotypes. Arginine 83-86 paraoxonase 1 Homo sapiens 42-46 32478190-8 2020 The result revealed 94.9% polymorphism of PON1 Q192R, which was higher in the R/R (Arg/Arg) genotypes than Q/R (Gln/Arg) and lowest in Q/Q (Gln/Gln) genotypes. Arginine 87-90 paraoxonase 1 Homo sapiens 42-46 25887882-4 2015 The most widely and accurately described is the single nucleotide polymorphism, which impacts the conversion of glutamine (Q) to arginine (R) and has the effect of altering the hydrolytic activity of the PON1 form. Arginine 129-137 paraoxonase 1 Homo sapiens 204-208 24705954-2 2014 Interindividual differences in activity of PON1 (catalytic bioscavenger) and substrate specificity are strongly associated with the substitution of two amino acids: Leu/Met (L/M) at position 55 (rs854560) and Gln/Arg (Q/R) at position 192 (rs662). Arginine 213-216 paraoxonase 1 Homo sapiens 43-47 25027835-2 2014 The PON1 gene has single nucleotide polymorphisms (SNPs) including a codon 192 arginine (R) to glutamine (Q) and methionine (M) to leucine (L) at codon 55. Arginine 79-87 paraoxonase 1 Homo sapiens 4-8 25734763-3 2015 PON1 activity shows great variability in the population as a result of a polymorphism in the coding sequence that is expressed as a Glu(Q)/Arg(R) substitution at position 192 of the amino acid sequence. Arginine 139-142 paraoxonase 1 Homo sapiens 0-4 25089090-2 2014 The PON1 gene contains several polymorphisms including a glutamine (Q) to arginine (R) transition at position 192 encoding circulating allozymes with higher antioxidant activity that might influence both parameters. Arginine 74-82 paraoxonase 1 Homo sapiens 4-8 23894162-1 2013 BACKGROUND: Paraoxonase 1 (PON1), an esterase that hydrolyzes toxic organophosphates and has antioxidative and antiatherogenic properties, contains a common polymorphism at position 192: glutamine (Q) or arginine (R). Arginine 204-212 paraoxonase 1 Homo sapiens 12-25 23894162-1 2013 BACKGROUND: Paraoxonase 1 (PON1), an esterase that hydrolyzes toxic organophosphates and has antioxidative and antiatherogenic properties, contains a common polymorphism at position 192: glutamine (Q) or arginine (R). Arginine 204-212 paraoxonase 1 Homo sapiens 27-31 21681430-2 2012 Little is known about the concomitant presence of the ACE gene D allele and paraoxonase (PON1) codon 192 arginine (Arg) on the severity of CAD. Arginine 105-113 paraoxonase 1 Homo sapiens 89-93 21681430-2 2012 Little is known about the concomitant presence of the ACE gene D allele and paraoxonase (PON1) codon 192 arginine (Arg) on the severity of CAD. Arginine 115-118 paraoxonase 1 Homo sapiens 89-93 21681430-3 2012 Regarding the high rate of CAD among Iranians the aim of present study was to examine the hypothesis of synergistic effects between ACE-D and PON1-Arg alleles on predisposition and the severity of CAD in our population. Arginine 147-150 paraoxonase 1 Homo sapiens 142-146 21681430-7 2012 We found that PON1 Arg 192 and ACE D allele act synergistically to increase the risk of CAD (OR 1.3, P = 0.044). Arginine 19-22 paraoxonase 1 Homo sapiens 14-18 21681430-8 2012 Our results showed a significant correlation between the possession of both PON1 192 Arg and the ACE D allele and the extent of CAD in CAD patients and CAD subjects without diabetes, represented by the increased frequency of three-vessel disease with OR 2.7, P = 0.046; chi(2) = 4, P = 0.046 and OR 2.4, P = 0.051; chi(2) = 3.8, P = 0.051, respectively. Arginine 85-88 paraoxonase 1 Homo sapiens 76-80 21681430-9 2012 We found that PON1 Arg 192 and ACE D alleles act synergistically to increase the risk of CAD in CAD patients and CAD subjects without diabetes from west of Iran, who have high frequency of three-vessel disease. Arginine 19-22 paraoxonase 1 Homo sapiens 14-18 21681430-10 2012 Our data suggest that PON1 192 Arg and the ACE D allele in combination with each other can be important independent risk factor for severity of CAD in patients carrying both PON1 192 Arg and the ACE D allele in a west population of Iran. Arginine 31-34 paraoxonase 1 Homo sapiens 22-26 21681430-10 2012 Our data suggest that PON1 192 Arg and the ACE D allele in combination with each other can be important independent risk factor for severity of CAD in patients carrying both PON1 192 Arg and the ACE D allele in a west population of Iran. Arginine 31-34 paraoxonase 1 Homo sapiens 174-178 21681430-10 2012 Our data suggest that PON1 192 Arg and the ACE D allele in combination with each other can be important independent risk factor for severity of CAD in patients carrying both PON1 192 Arg and the ACE D allele in a west population of Iran. Arginine 183-186 paraoxonase 1 Homo sapiens 22-26 21681430-10 2012 Our data suggest that PON1 192 Arg and the ACE D allele in combination with each other can be important independent risk factor for severity of CAD in patients carrying both PON1 192 Arg and the ACE D allele in a west population of Iran. Arginine 183-186 paraoxonase 1 Homo sapiens 174-178 21465165-1 2011 The role of the paraoxonase (PON1) codon 192 polymorphism [glutamine (Q)/arginine (R)] in coronary artery disease (CAD) is controversial. Arginine 73-81 paraoxonase 1 Homo sapiens 29-33 21465165-8 2011 We found a significant association between the PON1-Arg-192 genotype (QR + RR) and the extent of CAD in CAD patients and CAD subjects without diabetes, represented by the increased frequency of three-vessel disease with OR = 1.49, P = 0.046; chi2 = 3.82, P = 0.048 and OR = 1.46, P = 0.05; chi2 = 3.48, P = 0.051, respectively. Arginine 52-55 paraoxonase 1 Homo sapiens 47-51 21465165-9 2011 The CAD patients carrying PON1-Arg-192 genotype (QR + RR) had lower plasma HDL-C level (P = 0.019) and higher plasma LDL-C(P = 0.01) and TG(P = 0.05). Arginine 31-34 paraoxonase 1 Homo sapiens 26-30 21465165-10 2011 Our results indicated that PON1-Arg-192 allele can be important independent risk factor of CAD in a west population of Iran, with carriers of PON1-Arg-192 having an increased frequency of three-vessel disease and also having a distinct plasma lipids profile. Arginine 32-35 paraoxonase 1 Homo sapiens 27-31 21465165-10 2011 Our results indicated that PON1-Arg-192 allele can be important independent risk factor of CAD in a west population of Iran, with carriers of PON1-Arg-192 having an increased frequency of three-vessel disease and also having a distinct plasma lipids profile. Arginine 32-35 paraoxonase 1 Homo sapiens 142-146 21465165-10 2011 Our results indicated that PON1-Arg-192 allele can be important independent risk factor of CAD in a west population of Iran, with carriers of PON1-Arg-192 having an increased frequency of three-vessel disease and also having a distinct plasma lipids profile. Arginine 147-150 paraoxonase 1 Homo sapiens 27-31 21465165-10 2011 Our results indicated that PON1-Arg-192 allele can be important independent risk factor of CAD in a west population of Iran, with carriers of PON1-Arg-192 having an increased frequency of three-vessel disease and also having a distinct plasma lipids profile. Arginine 147-150 paraoxonase 1 Homo sapiens 142-146 20734577-4 2010 PON1 activity is under genetic control and its molecular basis is a polymorphism in the PON1 gene that shows two common isoforms: the wild Q form (192 Gln) with high ability to protect LDL from lipid peroxidation in vitro, and the mutated R (Arg) form with lower ability. Arginine 242-245 paraoxonase 1 Homo sapiens 0-4 21291901-7 2011 The PON1 activity toward paraoxonase was found to be significantly higher in the R/R (Arg/Arg) genotypes than Q/R (Gln/Arg) and lowest in Q/Q (Gln/Gln) genotypes in both workers and control subjects (p<0.001). Arginine 86-89 paraoxonase 1 Homo sapiens 4-8 21291901-7 2011 The PON1 activity toward paraoxonase was found to be significantly higher in the R/R (Arg/Arg) genotypes than Q/R (Gln/Arg) and lowest in Q/Q (Gln/Gln) genotypes in both workers and control subjects (p<0.001). Arginine 90-93 paraoxonase 1 Homo sapiens 4-8 21291901-7 2011 The PON1 activity toward paraoxonase was found to be significantly higher in the R/R (Arg/Arg) genotypes than Q/R (Gln/Arg) and lowest in Q/Q (Gln/Gln) genotypes in both workers and control subjects (p<0.001). Arginine 90-93 paraoxonase 1 Homo sapiens 4-8 20734577-4 2010 PON1 activity is under genetic control and its molecular basis is a polymorphism in the PON1 gene that shows two common isoforms: the wild Q form (192 Gln) with high ability to protect LDL from lipid peroxidation in vitro, and the mutated R (Arg) form with lower ability. Arginine 242-245 paraoxonase 1 Homo sapiens 88-92 19223938-3 2010 PON1 polymorphisms include a glutamine (Q)/arginine (R) substitution at position 192 (PON1(Q192R)) that affects hydrolysis of OP substrates, with the PON1(192Q) allotype hydrolyzing chlorpyrifos oxon less efficiently than the PON1(192R) allotype, a variation potentially important in determining susceptibility to chlorpyrifos. Arginine 43-51 paraoxonase 1 Homo sapiens 0-4 19939821-3 2010 Paraoxonase 1 polymorphism 192Gln/Arg influenced the risk of premature MI (P = .0054). Arginine 34-37 paraoxonase 1 Homo sapiens 0-13 19939821-5 2010 The association between PON1 genotype (192 Gln/Arg) and low-density lipoprotein cholesterol (LDL-C) (P = .036) levels was also observed. Arginine 47-50 paraoxonase 1 Homo sapiens 24-28 19939821-7 2010 PON1 polymorphism 192Gln/Arg influenced the risk of premature MI. Arginine 25-28 paraoxonase 1 Homo sapiens 0-4 19939821-8 2010 The association between PON1 genotype (192 Gln/Arg) and serum LDL-C levels may be explained by PON participation in reverse cholesterol transport. Arginine 47-50 paraoxonase 1 Homo sapiens 24-28 19939821-8 2010 The association between PON1 genotype (192 Gln/Arg) and serum LDL-C levels may be explained by PON participation in reverse cholesterol transport. Arginine 47-50 paraoxonase 1 Homo sapiens 24-27 19223938-3 2010 PON1 polymorphisms include a glutamine (Q)/arginine (R) substitution at position 192 (PON1(Q192R)) that affects hydrolysis of OP substrates, with the PON1(192Q) allotype hydrolyzing chlorpyrifos oxon less efficiently than the PON1(192R) allotype, a variation potentially important in determining susceptibility to chlorpyrifos. Arginine 43-51 paraoxonase 1 Homo sapiens 86-90 19223938-3 2010 PON1 polymorphisms include a glutamine (Q)/arginine (R) substitution at position 192 (PON1(Q192R)) that affects hydrolysis of OP substrates, with the PON1(192Q) allotype hydrolyzing chlorpyrifos oxon less efficiently than the PON1(192R) allotype, a variation potentially important in determining susceptibility to chlorpyrifos. Arginine 43-51 paraoxonase 1 Homo sapiens 86-90 19223938-3 2010 PON1 polymorphisms include a glutamine (Q)/arginine (R) substitution at position 192 (PON1(Q192R)) that affects hydrolysis of OP substrates, with the PON1(192Q) allotype hydrolyzing chlorpyrifos oxon less efficiently than the PON1(192R) allotype, a variation potentially important in determining susceptibility to chlorpyrifos. Arginine 43-51 paraoxonase 1 Homo sapiens 86-90 18347314-6 2008 RESULTS: There was a trend toward increased paraoxonase activity in ALS compared with controls (mean control paraoxonase 701.9 +/- 469.7 U/L, mean ALS 792.5 +/- 574.1 U/L; p = 0.066 after correction) which correlated with increased frequency of the homozygous arginine (RR) variant of PON1(Q192R) (p = 0.004). Arginine 260-268 paraoxonase 1 Homo sapiens 44-55 19003935-5 2008 Previously it was shown that there are two polymorphic areas on the PON1 gene: one causing a Leu --> Met substitution at 55th position, the other causing Gln --> Arg at the 192nd position. Arginine 168-171 paraoxonase 1 Homo sapiens 68-72 19280995-3 2008 Two common polymorphisms in the coding region of the PON1 gene, which lead to a glutamine (Q)/arginine (R) substitution at position 192 and a leucine (L)/methionine (M) substitution at position 55, influence PON1 activity. Arginine 94-102 paraoxonase 1 Homo sapiens 53-57 15681296-8 2005 This significant risk was restricted to those subject carriers of Arg (R) and Leu (L) allele of the PON1 192 and 55 variants and was confirmed in multiple logistic regression analysis. Arginine 66-69 paraoxonase 1 Homo sapiens 100-104 17010492-13 2007 The reason for this effect is probably based on the polymorphism of paraoxonase (PON1) in that the (192)arginine phenotype does hardly hydrolyze the arising diethylphosphoryl obidoxime. Arginine 104-112 paraoxonase 1 Homo sapiens 81-85 17936934-6 2007 PON1 is polymorphically distributed in human populations with an amino acid substitution (Gln/Arg) at position 192 of this 354-amino acid protein (the initiator Met residue is cleaved on maturation) that determines the catalytic efficiency of hydrolysis of some substrates. Arginine 94-97 paraoxonase 1 Homo sapiens 0-4 16120573-5 2005 A new coding polymorphism was detected in PON1 gene, which gives rise to amino acid substitutions of arginine (R) for glycine (G) at codon 160, whereas L54M polymorphism, which is common in white population, was not detected in our Han population. Arginine 101-109 paraoxonase 1 Homo sapiens 42-46 16239632-5 2005 RESULTS: A glutamine (Gln)/arginine (Arg) polymorphism at amino acid residue 192 in PON1 was significantly associated with stroke (P=0.003 in multivariate analysis, including age, sex, LDL, hypertension, diabetes, smoking, and pravastatin treatment as covariates). Arginine 27-35 paraoxonase 1 Homo sapiens 84-88 16239632-5 2005 RESULTS: A glutamine (Gln)/arginine (Arg) polymorphism at amino acid residue 192 in PON1 was significantly associated with stroke (P=0.003 in multivariate analysis, including age, sex, LDL, hypertension, diabetes, smoking, and pravastatin treatment as covariates). Arginine 37-40 paraoxonase 1 Homo sapiens 84-88 14527200-2 2003 Of the three genes in the paraoxonase gene family, PON1 shows a polymorphism, Gln 192 --> Arg, governed by two common alleles named *Q and *R. These determine two different isoforms associated, respectively, with lower and higher activity towards paraoxon, a toxic metabolic product of the insecticide parathion. Arginine 93-96 paraoxonase 1 Homo sapiens 26-37 15270786-0 2004 Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Arginine 18-21 paraoxonase 1 Homo sapiens 0-13 15270786-4 2004 Among the gene polymorphisms tested, the 192Gln/Arg polymorphism of PON1 was associated with the prevalence of retinopathy [odds ratio (OR) = 3.13, 95% confidence interval (CI) = 1.42-6.89, P = 0.0046, Gln/Gln vs. Gln/Arg and Arg/Arg]. Arginine 48-51 paraoxonase 1 Homo sapiens 68-72 15270786-4 2004 Among the gene polymorphisms tested, the 192Gln/Arg polymorphism of PON1 was associated with the prevalence of retinopathy [odds ratio (OR) = 3.13, 95% confidence interval (CI) = 1.42-6.89, P = 0.0046, Gln/Gln vs. Gln/Arg and Arg/Arg]. Arginine 218-221 paraoxonase 1 Homo sapiens 68-72 15270786-4 2004 Among the gene polymorphisms tested, the 192Gln/Arg polymorphism of PON1 was associated with the prevalence of retinopathy [odds ratio (OR) = 3.13, 95% confidence interval (CI) = 1.42-6.89, P = 0.0046, Gln/Gln vs. Gln/Arg and Arg/Arg]. Arginine 218-221 paraoxonase 1 Homo sapiens 68-72 15270786-4 2004 Among the gene polymorphisms tested, the 192Gln/Arg polymorphism of PON1 was associated with the prevalence of retinopathy [odds ratio (OR) = 3.13, 95% confidence interval (CI) = 1.42-6.89, P = 0.0046, Gln/Gln vs. Gln/Arg and Arg/Arg]. Arginine 218-221 paraoxonase 1 Homo sapiens 68-72 12849920-2 2003 Recent studies have suggested that glutamine(Q isoform)/arginine(R isoform) polymorphism at position 192 of PON(1) gene is associated with macrovascular disease of type 2 diabetes mellitus (T2DM). Arginine 56-64 paraoxonase 1 Homo sapiens 108-114 14527200-2 2003 Of the three genes in the paraoxonase gene family, PON1 shows a polymorphism, Gln 192 --> Arg, governed by two common alleles named *Q and *R. These determine two different isoforms associated, respectively, with lower and higher activity towards paraoxon, a toxic metabolic product of the insecticide parathion. Arginine 93-96 paraoxonase 1 Homo sapiens 51-55 12625227-3 2003 A glutamine/arginine (Gln/Arg) polymorphism at amino acid position 192 of PON has been described. Arginine 26-29 paraoxonase 1 Homo sapiens 74-77 12625227-4 2003 The Arg/Arg genotype is associated with higher serum paraoxonase activity compared to Gln/Gln. Arginine 4-7 paraoxonase 1 Homo sapiens 53-64 12625227-4 2003 The Arg/Arg genotype is associated with higher serum paraoxonase activity compared to Gln/Gln. Arginine 8-11 paraoxonase 1 Homo sapiens 53-64 12625227-5 2003 The Arg/Gln genotype is associated with intermediate serum PON activity. Arginine 4-7 paraoxonase 1 Homo sapiens 59-62 12525679-2 2003 Levels and genetic variability of the PON1 position 192 isoforms (Gln/Arg) influence sensitivity to specific insecticides or nerve agents and risk for cardiovascular disease. Arginine 70-73 paraoxonase 1 Homo sapiens 38-42 12454802-8 2003 However, among white women, when data were stratified by the number of diseased vessels, the frequency of the PON1 codon 192 Arg/Arg genotype was significantly higher in the group with three-vessel disease than in the other groups (those with one-vessel and two-vessel disease) combined (17.02% vs. 4.58%; P=.0066). Arginine 125-128 paraoxonase 1 Homo sapiens 110-114 12454802-8 2003 However, among white women, when data were stratified by the number of diseased vessels, the frequency of the PON1 codon 192 Arg/Arg genotype was significantly higher in the group with three-vessel disease than in the other groups (those with one-vessel and two-vessel disease) combined (17.02% vs. 4.58%; P=.0066). Arginine 129-132 paraoxonase 1 Homo sapiens 110-114 12454802-10 2003 The adjusted odds ratios for the development of three-vessel disease were 2.80 (95% confidence interval 1.06-7.37; P=.038) for PON1 codon 192 Arg/Arg and 3.68 (95% confidence interval 1.26-10.68; P=.017) for PON2 codon 311 Cys/Cys. Arginine 142-145 paraoxonase 1 Homo sapiens 127-131 12566597-0 2003 Lack of association between Alzheimer"s disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population. Arginine 56-59 paraoxonase 1 Homo sapiens 88-93 12566597-9 2003 These results suggest that the human Gln-Arg 192 Q/R polymorphism of the PON-1 gene is not associated with AD in an Italian population. Arginine 41-44 paraoxonase 1 Homo sapiens 73-78 15037822-1 2003 Human serum paraoxonase (PON1) exists in 2 major polymorphic forms: Q (glutamine) or R (arginine) at codon 192. Arginine 88-96 paraoxonase 1 Homo sapiens 25-29